The pharmaceuticalisation of society? A framework for analysis

Sociology of Health and Illness

Volumn 33, Issue 5, 2011, Pages 710-725

  Williams, Simon J ^a   Martin, Paul ^b   Gabe, Jonathan ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Consumers; Futures; Markets; Medicalisation; Medicines; Pharmaceuticalisation

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; DRUG CONTROL; DRUG DEVELOPMENT; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH STATUS; HUMAN; ORGANIZATION AND MANAGEMENT; SOCIAL BEHAVIOR;

DRUG AND NARCOTIC CONTROL; DRUG DISCOVERY; DRUG INDUSTRY; HEALTH STATUS; HUMANS; MARKETING OF HEALTH SERVICES; PRESCRIPTION DRUGS; SOCIAL IDENTIFICATION;

EID: 79960497480     PISSN: 01419889     EISSN: 14679566     Source Type: Journal    
DOI: 10.1111/j.1467-9566.2011.01320.x     Document Type: Article

References (70)

1. Abraham, J. (2009a) The pharmaceutical industry, the state and the NHS. In Gabe, J. and Calnan, M. (eds) The New Sociology of the Health Service. London: Routledge.
2. Abraham, J. (2009b) Sociology of pharmaceuticals development and regulation: a realist empirical research programme. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
3. Abraham, J. (2010) On the prohibition of conflicts of interest in pharmaceutical regulation: precautionary limits and permissive challenges. A commentary on Sismondo and O'Donovan and Lexchin, Social Science and Medicine, 70, 648-51.
4. Abraham, J. and Davis, C. (2005) Risking public safety: experts, the medical profession and 'acceptable' drug injury, Health, Risk and Society, 7, 379-95.
5. Abraham, J. and Lewis, G (2002) Citizenship, medical expertise and the regulatory state in Europe, Sociology, 36, 67-88.
6. Abraham, J.W. (1995) Science, Politics and the Pharmaceutical Industry. London: University College London Press.
7. Academy of Medical Sciences (2008) Brain Science, Addictions and Drugs. London: AMS.
8. Angell, M. (2005) The Truth about Drug Companies. New York: Random House.
9. Barr, M. and Rose, D. (2009) The great ambivalence; factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
10. Blech, J. (2006) Inventing Diseases and Pushing Pills. London: Routledge.
11. British Medical Association (2007) Boosting Your Brain Power: Ethical Aspects of Cognitive Enhancements. London: BMA.
12. Brown, N. (2003) Hope against hype: accountability in biopasts, presents and futures, Science Studies, 16, 3-2.
13. Brown, N. and Michael, M. (2003) A sociology of expectations: retrospecting prospects and prospecting retrospects, Technology Assessment and Strategic Management, 15, 3-18.
14. Brown, P., Zavestoski, S., McCormick, S., Mayer, B., et al. (2004) Embodied health movements: new approaches to social movements in health, Sociology of Health and Illness, 26, 1, 50-80.
15. Busfield, J. (2003) Globalization and the pharmaceutical industry revisited, International Journal of Health Services, 33, 581-603.
16. Busfield, J. (2010) 'A pill for every ill': explaining the expansion in medicine use, Social Science and Medicine, 70, 931-41.
17. Clarke, A, Fishman, J., Fosket, J.R., Mamo, L. and Shim, J. (2003) Biomedicalization: technoscientific transformations of health, illness and US biomedicine, American Sociological Review, 68, 161-94.
18. Conrad, P. (2005) The shifting engines of medicalization, Journal of Health and Social Behavior, 46, 3-14.
19. Conrad, P. (2007) The Medicalisation of Society. Baltimore: Johns Hopkins University Press
20. Conrad, P. and Leiter, V. (2004) Medicalization, markets and consumers, Journal of Health and Social Behavior, 45, 158-76.
21. Conrad, P. and Leiter, V. (2009) From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalization. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
22. Conrad, P., Mackie, T. and Mehrota, A. (2010) The costs of medicalization, Social Science and Medicine, 70, 1943-47.
23. Daemmrich, A. (2004) Pharmacopolitics. Chapel Hill: University of North Carolina.
24. Department of Health (2003) Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS. UK Government White Paper. London: Department of Health.
25. Elliot, C. (2003) Better Than Well: American Medicine Meets the American Dream. New York: W.W. Norton.
26. Fox, N.J. and Ward, K.J. (2009) Pharma in the bedroom ... and the kitchen. The pharmaceuticalisation of daily life. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
27. Fox, N.J., Ward, K.J. and O'Rourke, A.J. (2005a) The 'expert patient': empowerment or medical dominance? The case of weight loss, pharmaceutical drugs and the internet, Social Science and Medicine, 60, 1299-309.
28. Fox, N.J., Ward, K.J. and O'Rourke, A.J. (2005b) Pro-anorexia, weight-loss drugs and the internet: an 'anti-recovery' explanatory model of anorexia, Sociology of Health and Illness, 27, 7, 944-71.
29. Fox, N.J., Ward, K.J. and O'Rourke, A.J. (2007) A sociology of technology governance for the information age: the case of pharmaceuticals, consumer advertising and the internet, Sociology, 40, 315-34.
30. Gabe, J. and Bury, M. (1996a) Halcyon nights: a sociological account of a medical controversy, Sociology, 30, 447-69.
31. Gabe, J. and Bury, M. (1996b) Risking tranquilliser use: cultural and lay dimensions. In Williams, S. and Calnan, M. (eds) Modern Medicine. London: University College London Press.
32. Gabe, J. and Lipshitz-Phillips, S. (1984) Tranquillisers as social control? Sociological Review, 32, 524-46.
33. Garattini, S. and Bertele, V. (2001) Adjusting Europe's drug regulation to public health needs, The Lancet, 358, 66.
34. Gibbon, S. and Novas, C. (eds) Biosocialities, Genetics and the Social Sciences. London: Routledge.
35. Goodman, J. and Walsh, V. (1993) Little and Big Heuristics: medicine, chemistry and pharmaceutical production in nineteenth-century Europe. Paper given at Society for the History of Technology (SHOT), Conference on Technological Change, Oxford, 8-11 September 1993.
36. Greely, H., Sahakian, B., Harris, J., Kessler, R.C., et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy, Nature, 456, 702-5.
37. Hedgecoe, A. (2004) The Politics of Personalised Medicine. Cambridge: Cambridge University Press.
38. Hedgecoe, A. and Martin, P. (2003) The drugs don't work: expectations and the shaping of pharmacogenetics, Social Studies of Science, 33, 327-64.
39. Hopkins, M.H., Martin, P.A., Nightingale, P., Kraft, A., et al. (2007) The myth of the biotech revolution: an assessment of technological, clinical and organisational change, Research Policy, 36, 566-89.
40. House of Commons Health Committee (2005) The Influence of the Pharmaceutical Industry (Fourth Report for Session 2004-5). London: Stationery Office.
41. IMS Heath (2010) Press releases: IMS health forecasts. Available at (last accessed 6 December 2010).
42. Jones, K. (2009) In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
43. Kelleher, D. (2004) Self help groups and their relationship to medicine. In Kelleher, D., Gabe, J. and Williams, G. (eds) (2004) Challenging Medicine. 2nd edition, London: Routledge.
44. Kuemmerle, W. (1999) Foreign direct investment in industrial research in the pharmaceutical and electronics industries - results from a survey of multinational firms, Research Policy, 28, 179-93.
45. Kroll-Smith, S. (2003) Popular media and 'excessive sleepiness', Sociology of Health and Illness, 25, 6, 625-43.
46. Law, J. (2006) The Big Pharma. London: Constable and Robinson.
47. Lexchin, J. (2006) Bigger and better: how Pfizer redefined erectile dysfunction, Public Library of Science Medicine, 3, e132.
48. Martin, E. (2006) The pharmaceutical person, Biosocieties, 1, 273-88.
49. Moynihan, R. (2002) Disease-mongering: how doctors, drug companies, and insurers are making you feel sick, British Medical Journal, 324, 923.
50. Moynihan, R. and Cassels, A. (2005) Selling Sickness. New York: Nation Books.
51. Moynihan, R. and Henry, D. (2006) The fight against disease mongering: generating knowledge for action, Public Library of Science Medicine, 3e, 191.
52. Nettleton, S., Burrows, R. and O'Malley, L. (2005) The mundane realities of the everyday lay use of the internet for health, and their consequences for media convergence, Sociology of Health and Illness, 27, 7, 972-92.
53. Nightingale, P. and Martin, P.A. (2004) The myth of the biotech revolution, Trends in Biotechnology, 22, 564-69.
54. Novas, C. (2006) The political economy of hope: patients' organizations, science and biovalue, Biosocieties, 1, 289-305.
55. Office of Science and Technology Department of Trade and Industry (2005) Drugs Futures 2025. London: DTI.
56. Rose, N. (2007) The Politics of Life Itself. Princeton: Princeton University Press.
57. Scambler, G. (ed.) (2006) Habermas, Critical Theory and Health. London: Routledge.
58. Seale, C. (2002) Media and Health. London: Sage.
59. Seale, C. (2005) New directions for critical internet health studies, Sociology of Health and Illness., 27, 4, 515-40.
60. Stevenson, F., Britten, N., Barry, C., Bradley, C. and Barber, N. (2002) Perceptions of legitimacy: the influence on medicine taking and prescribing, Health, 6, 85-104.
61. Stevenson, F., Leontowitsch, M. and Duggan, C. (2009) Over-the-counter medicines: professional expertise and consumer discourses. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
62. Taylor, D. and Bury, M. (2007) Chronic illness, expert patients and care transition, Sociology of Health and Illness, 29, 1, 27-45.
63. Teifer, L. (2006) Female sexual dysfunction: a case study of disease mongering and activist resistance, Public Library of Science -Medicine, 3, e.178.
64. Van Lente, H. (1993) Promising Technology: the Dynamics of Expectations in Technological Development. Enschede: University of Twente.
65. Webster, A., Martin, P.A., Lewis, G. and Smart, A. (2004) Integrating pharmacogenetics into society: in search of a model? Nature Reviews Genetics., 5, 663-69.
66. Weiss, M.C. and Sutton, J. (2009) The changing nature of prescribing, Sociology of Health and Illness, 31, 3, 406-21.
67. Williams, S.J. and Calnan, M. (eds) (1966) Modern Medicine: Lay Perspectives and Experiences. London: University College London Press.
68. Williams, S.J. and Martin, P.A. (2008) Risks and benefits may turn out to be finely balanced, Nature, 457, 532.
69. Williams, S.J., Seale, C., Boden, S., Lowe, P., et al. (2009) Waking up to sleepiness: modafinil, the media and the pharmaceuticalisation of everyday/night life. In Williams, S.J., Gabe, J. and Davis, P. (eds) Pharmaceuticals and Society: Critical Discourses and Debates. Oxford: Blackwell.
70. Woloshin, S. and Schwartz, L.M. (2006) Giving legs to restless legs: a case study of how the media help make people sick, Public Library of Science Medicine, 3, e170-8.